Cargando…

TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer

Immunotherapy, a chemotherapy-free process, has emerged as a promising therapeutic strategy to prolong the overall survival (OS) of patients with non-small-cell lung cancer (NSCLC). However, effective stratification factors for immunotherapy remain unclear. The purpose of this study was to discuss t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Jun, Zhong, Runbo, Lou, Yuqing, Hu, Minjuan, Yang, Zhengyu, Wang, Yanan, Chen, Ya, Zou, Benkun, Zhang, Wei, Wang, Huimin, Han, Baohui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485033/ https://www.ncbi.nlm.nih.gov/pubmed/34603310 http://dx.doi.org/10.3389/fimmu.2021.732125

Ejemplares similares

ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients
por: Lu, Jun, et al.
Publicado: (2021)

Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung Cancer
por: Yang, Zhengyu, et al.
Publicado: (2022)

The clinicopathological and molecular characteristics of resected EGFR‐mutant lung adenocarcinoma
por: Zhou, Wensheng, et al.
Publicado: (2022)

Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations
por: Yang, Zhengyu, et al.
Publicado: (2021)

Editorial: Complement and Immunotherapeutics
por: Okrój, Marcin, et al.
Publicado: (2021)

Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma
por: Li, Wenting, et al.
Publicado: (2023)

Revealing the role of regulatory T cells in the tumor microenvironment of lung adenocarcinoma: a novel prognostic and immunotherapeutic signature
por: Zhang, Pengpeng, et al.
Publicado: (2023)

Immunometabolism characteristics and a potential prognostic risk model associated with TP53 mutations in breast cancer
por: Jiang, Mengping, et al.
Publicado: (2022)

Immunotherapeutic Potential of Extracellular Vesicles
por: Zhang, Bin, et al.
Publicado: (2014)

Editorial: Glycoconjugates in vaccines and immunotherapeutics
por: Shivatare, Sachin, et al.
Publicado: (2022)

A TP53 Related Immune Prognostic Model for the Prediction of Clinical Outcomes and Therapeutic Responses in Lung Adenocarcinoma
por: Zhang, Xiaonan, et al.
Publicado: (2022)

Medulloblastoma: From TP53 Mutations to Molecular Classification and Liquid Biopsy
por: Eibl, Robert H., et al.
Publicado: (2023)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Paclitaxel Has a Reduced Toxicity Profile in Healthy Rats After Polymeric Micellar Nanoparticle Delivery
por: Lu, Jun, et al.
Publicado: (2023)

Editorial: Advances in Immunotherapeutic Approaches to Tuberculosis
por: Estrada García, Iris, et al.
Publicado: (2021)

TP53I13 promotes metastasis in glioma via macrophages, neutrophils, and fibroblasts and is a potential prognostic biomarker
por: Ge, Xinqi, et al.
Publicado: (2022)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers
por: Biatta, Chiara M., et al.
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
por: Chen, Ya, et al.
Publicado: (2021)

Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
por: Chen, Ya, et al.
Publicado: (2021)

A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer
por: Wu, Xiangkun, et al.
Publicado: (2020)

Individualized prognosis stratification in muscle invasive bladder cancer: A pairwise TP53-derived transcriptome signature
por: Liu, Hua-Ping, et al.
Publicado: (2023)

Association Analyses of TP53 Mutation With Prognosis, Tumor Mutational Burden, and Immunological Features in Acute Myeloid Leukemia
por: Wen, Xiang-mei, et al.
Publicado: (2021)

NKT Cells as an Ideal Anti-Tumor Immunotherapeutic
por: Fujii, Shin-ichiro, et al.
Publicado: (2013)

Editorial: Immunotherapeutic and Immunoprophylactic Strategies for Infectious Diseases
por: Sautto, Giuseppe A., et al.
Publicado: (2020)

TREX1 as a Novel Immunotherapeutic Target
por: Hemphill, Wayne O., et al.
Publicado: (2021)

Editorial: “AAV Gene Therapy: Immunology and Immunotherapeutics”
por: Martinez-Navio, José M., et al.
Publicado: (2021)

Immunotherapeutic progress and application of bispecific antibody in cancer
por: Kang, Jingyue, et al.
Publicado: (2022)

P1155: MORE PRECISE RISK STRATIFICATION FOR TP53 MUTANT DIFFUSE LARGE B CELL LYMPHOMA
por: Du, Kai-Xin, et al.
Publicado: (2023)

TP53 Mutational Status Is a Potential Marker for Risk Stratification in Wilms Tumour with Diffuse Anaplasia
por: Maschietto, Mariana, et al.
Publicado: (2014)

hTERT, MYC and TP53 deregulation in gastric preneoplastic lesions
por: Silva, Tanielly Cristina Raiol, et al.
Publicado: (2012)

Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy
por: Guo, Liang, et al.
Publicado: (2020)

Immunogenomic Landscape in Breast Cancer Reveals Immunotherapeutically Relevant Gene Signatures
por: Wang, Tao, et al.
Publicado: (2022)

Integrated single-cell RNA-seq analysis identifies immune heterogeneity associated with KRAS/TP53 mutation status and tumor-sideness in colorectal cancers
por: Liu, Xiaoyu, et al.
Publicado: (2022)

Comparative Study of Pulmonary Combined Large-Cell Neuroendocrine Carcinoma and Combined Small-Cell Carcinoma in Surgically Resected High-Grade Neuroendocrine Tumors of the Lung
por: Wang, Yanan, et al.
Publicado: (2021)

Advancing Immunotherapeutic Vaccine Strategies Against Pulmonary Tuberculosis
por: Afkhami, Sam, et al.
Publicado: (2020)

Treg: A Promising Immunotherapeutic Target in Oral Diseases
por: Zhang, Yujing, et al.
Publicado: (2021)

The TP53 gene rs1042522 C>G polymorphism and neuroblastoma risk in Chinese children
por: He, Jing, et al.
Publicado: (2017)

Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance
por: Li, Yujing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l20fjj6c7s5fhoukb7png4snqb